Grantham, Mayo, Van Otterloo & Co (GMO)’s CytomX Therapeutics CTMX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-115,084	Closed	-$754K	–	858
2020 Q4	$754K	Sell	115,084 -110,416	-49%	-$789K	﹤0.01%	613
2020 Q3	$1.5M	Buy	225,500 +74,000	+49%	+$549K	0.01%	457
2020 Q2	$1.26M	Buy	151,500 +132,500	+697%	+$1.23M	0.01%	496
2020 Q1	$146K	Buy	+19,000	New	+$132K	﹤0.01%	718
2018 Q3	–	Sell	-14,900	Closed	-$341K	–	541
2018 Q2	$341K	Hold	14,900	–	–	﹤0.01%	498
2018 Q1	$424K	Hold	14,900	–	–	﹤0.01%	493
2017 Q4	$315K	Buy	+14,900	New	+$309K	﹤0.01%	510

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CTMX Position: Q1 2021 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 115,084 shares — an estimated $754K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CTMX in Q4 2017 and held it in 7 quarters. The position peaked at $1.5M in Q3 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 115,084 CytomX Therapeutics shares in Q1 2021, an estimated $754K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CytomX Therapeutics in Q4 2017 and held it in 7 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s CytomX Therapeutics position peaked at $1.5M in Q3 2020.
126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2021, filed 13 May 2021.